Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target

Establishment of NS3 tumor cell line expressing Hepatitis C virus Non-structural Protein 3 as valuable tool for HCV challenging in mice

Introduction: Hepatitis C virus (HCV) is one of the major medical problems. Human and chimpanzees are the only specific hosts which are naturally susceptible to HCV infection. Mice and other common laboratory animals are resistant to the virus, hence HCV prophylactic and therapeutic researches are very difficult and challenging. HCV non-structural protein 3 (NS3) is one of the most attractive t...

construction and immunogenicity analysis of hepatitis c virus (hcv) truncated non-structural protein 3 (ns3) plasmid vaccine

conclusions the pc-ns3 possesses the capacity to express ns3 in the mammalian cell line and demonstrated strong immunogenicity in a murine model. our primary results demonstrated that the immunogenic truncated region of ns3 could be used as a potential vaccine candidate against hepatitis c. results the pcdna3.1 plasmid harboring the coding sequence of ns3 (pc-ns3) was constructed and confirmed ...

Analysis of Immumoreactivity of Heterologously Expressed Non-structural Protein 4B (NS4B) from Hepatitis C Virus (HCV) Genotype 1a

Background: Detection of hepatitis C virus specific antibodies is the initial step in chronic HCV diagnosis.  HCV NS4B is among the most immunogenic HCV antigens and has been widely used in commercial Enzyme Immunoassays (EIA). Additionally, NS4B, a key protein in the virus replication, can be an alternative target for antiviral therapy. Objectives: Development of a new method for high-level ex...

Performance of NS3, NS5a AND NS5b Hepatitis C Virus (HCV) Antiviral Resistance Sequencing Assays

VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.

The NS3-4A serine protease of hepatitis C virus (HCV) is essential for viral replication and therefore has been one of the most attractive targets for developing specific antiviral agents against HCV. VX-950, a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, is currently in clinical development for the treatment of hepatitis C. In this report, we de...